Market Research Life Sciences Market Research Biotechnology Market Research Stem Cell Market Research

Cell and Gene Therapy Manufacturing Quality Control (QC) Market (Component: Equipment & Accessories, Consumables, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 202 Pages Transparency Market Research Pvt. Ltd. August, 2023 TNPR18249863
Best Price Guarantee
Price from $5,795
Length 202 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date August, 2023
SKU TNPR18249863

Cell and Gene Therapy Manufacturing Quality Control (QC) Market (Component: Equipment & Accessories, Consumables, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Cell and Gene Therapy Manufacturing Quality Control (QC) Market – Scope of Report

TMR’s report on the global cell and gene therapy manufacturing quality control (QC) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell and gene therapy manufacturing quality control (QC) market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell and gene therapy manufacturing quality control (QC) market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cell and gene therapy manufacturing quality control (QC) market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell and gene therapy manufacturing quality control (QC) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell and gene therapy manufacturing quality control (QC) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell and gene therapy manufacturing quality control (QC) market.

The report delves into the competitive landscape of the global cell and gene therapy manufacturing quality control (QC) market. Key players operating in the global cell and gene therapy manufacturing quality control (QC) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell and gene therapy manufacturing quality control (QC) market profiled in this report.

Key Questions Answered in Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market Report
  • What is the sales/revenue generated by cell and gene therapy manufacturing quality control (QC) across all regions during the forecast period?
  • What are the opportunities in the global cell and gene therapy manufacturing quality control (QC) market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Cell and Gene Therapy Manufacturing Quality Control (QC) Market – Research Objectives and Research Approach

The comprehensive report on the global cell and gene therapy manufacturing quality control (QC) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell and gene therapy manufacturing quality control (QC) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell and gene therapy manufacturing quality control (QC) market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Key Industry Events
5.3. Regulatory Scenario by Region/Globally
5.4. Major Research Institutes Involved
5.5. COVID-19 Pandemic Impact on Industry
6. Global Cell and Gene Therapy Manufacturing QC Analysis and Forecast, by Component
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Component, 2017-2031
6.3.1. Equipment & Accessories
6.3.2. Consumables
6.3.3. Others
6.4. Market Attractiveness Analysis, by Component
7. Global Cell and Gene Therapy Manufacturing QC Analysis and Forecast, by Analytical Method
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Analytical Method, 2017-2031
7.3.1. Sterility Testing
7.3.2. Purity Testing
7.3.3. Potency Testing
7.3.4. Identity Testing
7.3.5. Others
7.4. Market Attractiveness Analysis, by Analytical Method
8. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by Process
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Process, 2017-2031
8.3.1. Upstream Processes
8.3.2. Downstream Processes
8.3.3. Process Development
8.4. Market Attractiveness Analysis, by Process
9. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Pharmaceutical & Biotechnology Companies
9.3.2. Contract Manufacturing Organizations (CMOs)
9.4. Market Attractiveness Analysis, by End-user
10. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Component, 2017-2031
11.2.1. Equipment & Accessories
11.2.2. Consumables
11.2.3. Others
11.3. Market Value Forecast, by Analytical Method, 2017-2031
11.3.1. Sterility Testing
11.3.2. Purity Testing
11.3.3. Potency Testing
11.3.4. Identity Testing
11.3.5. Others
11.4. Market Value Forecast, by Process, 2017-2031
11.4.1. Upstream Processes
11.4.2. Downstream Processes
11.4.3. Process Development
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Pharmaceutical & Biotechnology Companies
11.5.2. Contract Manufacturing Organizations (CMOs)
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Component
11.7.2. By Analytical Method
11.7.3. By Process
11.7.4. By End-user
11.7.5. By Country
12. Europe Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Component, 2017-2031
12.2.1. Equipment & Accessories
12.2.2. Consumables
12.2.3. Others
12.3. Market Value Forecast, by Analytical Method, 2017-2031
12.3.1. Sterility Testing
12.3.2. Purity Testing
12.3.3. Potency Testing
12.3.4. Identity Testing
12.3.5. Others
12.4. Market Value Forecast, by Process, 2017-2031
12.4.1. Upstream Processes
12.4.2. Downstream Processes
12.4.3. Process Development
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Pharmaceutical & Biotechnology Companies
12.5.2. Contract Manufacturing Organizations (CMOs)
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Component
12.7.2. By Analytical Method
12.7.3. By Process
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Component, 2017-2031
13.2.1. Equipment & Accessories
13.2.2. Consumables
13.2.3. Others
13.3. Market Value Forecast, by Analytical Method, 2017-2031
13.3.1. Sterility Testing
13.3.2. Purity Testing
13.3.3. Potency Testing
13.3.4. Identity Testing
13.3.5. Others
13.4. Market Value Forecast, by Process, 2017-2031
13.4.1. Upstream Processes
13.4.2. Downstream Processes
13.4.3. Process Development
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Pharmaceutical & Biotechnology Companies
13.5.2. Contract Manufacturing Organizations (CMOs)
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Component
13.7.2. By Analytical Method
13.7.3. By Process
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Component, 2017-2031
14.2.1. Equipment & Accessories
14.2.2. Consumables
14.2.3. Others
14.3. Market Value Forecast, by Analytical Method, 2017-2031
14.3.1. Sterility Testing
14.3.2. Purity Testing
14.3.3. Potency Testing
14.3.4. Identity Testing
14.3.5. Others
14.4. Market Value Forecast, by Process, 2017-2031
14.4.1. Upstream Processes
14.4.2. Downstream Processes
14.4.3. Process Development
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Pharmaceutical & Biotechnology Companies
14.5.2. Contract Manufacturing Organizations (CMOs)
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Component
14.7.2. By Analytical Method
14.7.3. By Process
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Component, 2017-2031
15.2.1. Equipment & Accessories
15.2.2. Consumables
15.2.3. Others
15.3. Market Value Forecast, by Analytical Method, 2017-2031
15.3.1. Sterility Testing
15.3.2. Purity Testing
15.3.3. Potency Testing
15.3.4. Identity Testing
15.3.5. Others
15.4. Market Value Forecast, by Process , 2017-2031
15.4.1. Upstream Processes
15.4.2. Downstream Processes
15.4.3. Process Development
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Pharmaceutical & Biotechnology Companies
15.5.2. Contract Manufacturing Organizations (CMOs)
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Component
15.7.2. By Analytical Method
15.7.3. By Process
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2022
16.3. Company Profiles
16.3.1. bioMérieux SA
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategies
16.3.1.5. Recent Developments
16.3.2. Bio-Rad Laboratories, Inc.
16.3.2.1. Company Overview
16.3.2.2. Financial Overview
16.3.2.3. Product Portfolio
16.3.2.4. Business Strategies
16.3.2.5. Recent Developments
16.3.3. Bio-Techne Corporation
16.3.3.1. Company Overview
16.3.3.2. Financial Overview
16.3.3.3. Product Portfolio
16.3.3.4. Business Strategies
16.3.3.5. Recent Developments
16.3.4. QIAGEN
16.3.4.1. Company Overview
16.3.4.2. Financial Overview
16.3.4.3. Product Portfolio
16.3.4.4. Business Strategies
16.3.4.5. Recent Developments
16.3.5. Charles River Laboratories International, Inc.
16.3.5.1. Company Overview
16.3.5.2. Financial Overview
16.3.5.3. Product Portfolio
16.3.5.4. Business Strategies
16.3.5.5. Recent Developments
16.3.6. Lonza Group AG
16.3.6.1. Company Overview
16.3.6.2. Financial Overview
16.3.6.3. Product Portfolio
16.3.6.4. Business Strategies
16.3.6.5. Recent Developments
16.3.7. Merck KGaA
16.3.7.1. Company Overview
16.3.7.2. Financial Overview
16.3.7.3. Product Portfolio
16.3.7.4. Business Strategies
16.3.7.5. Recent Developments
16.3.8. Intertek Group plc
16.3.8.1. Company Overview
16.3.8.2. Financial Overview
16.3.8.3. Product Portfolio
16.3.8.4. Business Strategies
16.3.8.5. Recent Developments
16.3.9. Thermo Fisher Scientific Inc.
16.3.9.1. Company Overview
16.3.9.2. Financial Overview
16.3.9.3. Product Portfolio
16.3.9.4. Business Strategies
16.3.9.5. Recent Developments
16.3.10. Eurofins Scientific S.E.
16.3.10.1. Company Overview
16.3.10.2. Financial Overview
16.3.10.3. Product Portfolio
16.3.10.4. Business Strategies
16.3.10.5. Recent Developments
16.3.11. F. Hoffmann-La Roche Ltd.
16.3.11.1. Company Overview
16.3.11.2. Financial Overview
16.3.11.3. Product Portfolio
16.3.11.4. Business Strategies
16.3.11.5. Recent Developments

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings